Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PAHC 
Phibro Animal Health Corporation (PAHC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/27/2025: PAHC (4-star) is a STRONG-BUY. BUY since 8 days. Profits (3.04%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $26
1 Year Target Price $26
| 0 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 2 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 63.19% | Avg. Invested days 48 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.31B USD | Price to earnings Ratio 41.28 | 1Y Target Price 26 |
Price to earnings Ratio 41.28 | 1Y Target Price 26 | ||
Volume (30-day avg) 4 | Beta 0.8 | 52 Weeks Range 16.08 - 32.95 | Updated Date 08/27/2025 |
52 Weeks Range 16.08 - 32.95 | Updated Date 08/27/2025 | ||
Dividends yield (FY) 1.47% | Basic EPS (TTM) 0.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-27 | When - | Estimate 0.52 | Actual - |
Profitability
Profit Margin 2.67% | Operating Margin (TTM) 11.39% |
Management Effectiveness
Return on Assets (TTM) 6.26% | Return on Equity (TTM) 11.86% |
Valuation
Trailing PE 41.28 | Forward PE 10.57 | Enterprise Value 2022683964 | Price to Sales(TTM) 1.1 |
Enterprise Value 2022683964 | Price to Sales(TTM) 1.1 | ||
Enterprise Value to Revenue 1.7 | Enterprise Value to EBITDA 16.38 | Shares Outstanding 20367600 | Shares Floating 20190195 |
Shares Outstanding 20367600 | Shares Floating 20190195 | ||
Percent Insiders 0.8 | Percent Institutions 105.02 |
Upturn AI SWOT
Phibro Animal Health Corporation
Company Overview
History and Background
Phibro Animal Health Corporation was founded in 1916. Initially a trading company, it evolved into a global animal health and nutrition company. It IPO'd in 2014. It focuses on developing, manufacturing, and marketing a broad range of animal health and nutrition products.
Core Business Areas
- Animal Health: Develops, manufactures, and markets a variety of products, including medicated feed additives, nutritional specialty products, and vaccines, aimed at improving animal health and productivity. Focuses on prevention and treatment of diseases.
- Nutritional Specialties: Offers a portfolio of nutritional specialty products used as ingredients in feed and food for animals, promoting growth, health, and well-being. This includes mineral nutrition.
- Performance Alternatives: Provides alternatives to traditional animal health products, focusing on enhanced animal performance and welfare. Includes products that promote gut health.
Leadership and Structure
Jack H. Bendheim serves as Chairman, President and Chief Executive Officer. The company operates with a global structure, dividing its operations based on geography and product categories. Board includes individuals with experience in pharmaceuticals, finance, and animal health.
Top Products and Market Share
Key Offerings
- Aviax/Emtry: Medicated feed additives for poultry. Market share data is difficult to pinpoint precisely, but is a significant player. Competitors include Elanco (ELAN) and Zoetis (ZTS).
- Probiotech: Nutritional specialty product enhancing animal performance. Market share data is difficult to pinpoint precisely. Competitors include Cargill and ADM.
- Phibro Vaccines: Range of vaccines for various animal species. Gaining traction in the market. Competitors include Merck Animal Health (MRK) and Zoetis (ZTS).
Market Dynamics
Industry Overview
The animal health industry is driven by growing demand for animal protein, increasing awareness of animal welfare, and rising concerns about food safety. It's characterized by innovation in animal health products, including vaccines and nutritional supplements.
Positioning
Phibro is positioned as a global leader in animal health and nutrition. It competes based on product innovation, global reach, and strong customer relationships.
Total Addressable Market (TAM)
The global animal health market is estimated to be over $50 billion. Phibro, with its diverse portfolio, is positioned to capture a meaningful share. Specific TAM segment data would need further research. Phibrou2019s TAM is related to Livestock production.
Upturn SWOT Analysis
Strengths
- Strong global presence
- Diverse product portfolio
- Established customer relationships
- Focus on innovation
- Experienced management team
Weaknesses
- Dependence on livestock production cycles
- Exposure to regulatory changes
- Commodity price fluctuations impacting raw materials
- Smaller R&D budget relative to bigger players
Opportunities
- Expanding into emerging markets
- Developing new product lines
- Acquiring complementary businesses
- Increasing demand for sustainable animal production practices
Threats
- Intense competition
- Changing consumer preferences
- Disease outbreaks
- Economic downturns
- Increased regulation
Competitors and Market Share
Key Competitors
- ELAN
- ZTS
- MRK
Competitive Landscape
Phibro faces intense competition from larger, more diversified animal health companies. Its advantages include its focused product portfolio and strong customer relationships in key markets. Needs to increase R&D to compete with bigger firms.
Major Acquisitions
MMI Holdings Limited
- Year: 2018
- Acquisition Price (USD millions): 75
- Strategic Rationale: Expanded Phibro's presence in the aquaculture market.
Growth Trajectory and Initiatives
Historical Growth: Phibro has demonstrated steady growth through both organic initiatives and acquisitions.
Future Projections: Analyst estimates vary, but generally project continued growth driven by the increasing demand for animal protein.
Recent Initiatives: Phibro has recently focused on expanding its product offerings in nutritional specialties and performance alternatives. Also has been buying back shares.
Summary
Phibro Animal Health is a global player in animal health and nutrition, with a diverse product portfolio and a strong customer base. The company's strengths include its global presence and focus on innovation. However, it faces intense competition and is subject to regulatory changes. Its smaller market capitalization also makes it more vulnerable to market shocks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Phibro Animal Health Corporation Investor Relations
- Industry Reports
- Market Analysis Reports
- SEC Filings
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Market conditions and company performance can change rapidly. Conduct thorough research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Phibro Animal Health Corporation
Exchange NASDAQ | Headquaters Teaneck, NJ, United States | ||
IPO Launch date 2014-04-11 | Chairman, President & CEO Mr. Jack Clifford Bendheim | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1940 | Website https://www.pahc.com |
Full time employees 1940 | Website https://www.pahc.com | ||
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.